Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer PURPOSE: Few studies have examined the ...
At the recent CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York Lung Cancer Symposium, Dr ...
Scientists at The Wistar Institute have solved a longstanding puzzle in ovarian cancer treatment: why anti-estrogen therapy often fails even when tumors express the hormone receptor that should make ...
Restoring P53's autonomous anti-cancer function through P53 mRNA delivery is a promising anti-tumor strategy. Yet, in tumors harboring mutant P53, the existing mutant P53 (Mutp53) would interferes ...
Researchers at the University of Michigan Rogel Cancer Center and School of Dentistry found that certain drugs can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid ...
Phase I Trials in Pediatric Oncology: Perceptions of Pediatricians From the United Kingdom Children’s Cancer Study Group and the Pediatric Oncology Group PURPOSE: The loss of p53 function is a ...
Inactivation of the tumor suppressor p53 occurs in approximately half of human cancer cases. In particular, the Y220C point mutation, which induces p53 misfolding and inactivation, is found in about 1 ...
The effects of p53 in cancer-associated fibroblasts on cancer cell migration: Cancer cells (magenta) migrate in the direction of cancer-associated fibroblasts (yellow) that express a non-mutated p53 ...
"It's going against dogma: The field thinks p53 mutant automatically is stable" and produces metastasis. "p53 mutational status in tumors may dictate the response to therapy in more ways than ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback